A Phase 3 interventional study of B/F/TAF and Placebo to match DTG in HIV-1/HBV Co-Infection, sponsored by Gilead Sciences. Completed at 69 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-19.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the efficacy of fixed-dose combination (FDC) of bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + emtricitabine/tenofovir disoproxil fumarate (F/TDF) in treatment-naïve and HIV-1 and hepatitis B virus (HBV) adults.
92 studies on the registry are indexed under Coinfection; 12 are open to participants now.
This study's enrollment of 244 is above the median of 75 across 50 interventional studies indexed under Coinfection.
Browse Coinfection studies →Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
type 1 (HIV-1) co-infection:
co-infection:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who are HIV-1 and HBV co-infected and treatment-naïve will receive Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) fixed-dose combination (FDC) tablet in addition to placebo to match (PTM) dolutegravir (DTG) tablet and PTM FDC emtricitabine/ tenofovir desoproxil fumarate (F/TDF) tablet for 96 weeks.
Drug: B/F/TAF · Drug: Placebo to match DTG · Drug: Placebo to match F/TDF
Participants who are HIV-1 and HBV co-infected and treatment-naïve will receive DTG and FDC F/TDF in addition to PTM B/F/TAF for 96 weeks.
Drug: DTG · Drug: F/TDF · Drug: Placebo to match B/F/TAF
After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label extension phase for up to 48 weeks, or until the product becomes accessible through an access program, or until Gilead elects to discontinue the study in that country, whichever occurs first.
Drug: B/F/TAF
After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label extension phase for up to 48 weeks, or until the product becomes accessible through an access program, or until Gilead elects to discontinue the study in that country, whichever occurs first.
Drug: B/F/TAF
Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide
50/200/25 mg B/F/TAF FDC tablet administered orally once daily, without regard to food
Also known as: Biktarvy®
Tablet administered orally once daily, without regard to food
Tablet administered orally once daily, without regard to food
50 mg tablet administered orally once daily, without regard to food
200/300 mg tablet administered orally once daily, without regard to food
Also known as: Truvada®
Tablet administered orally once daily, without regard to food
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm (Co-primary Endpoint)
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Percentages were rounded-off.
Time frame: Week 48
Percentage of Participants With Plasma Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48 as Defined by Missing = Failure Approach (Co-primary Endpoint)
This outcome measure was analyzed using a Missing = Failure approach. In this approach, all missing data were treated as HBV DNA ≥ 29 IU/mL. Percentages were rounded-off.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which was defined as a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Percentages were rounded-off.
Time frame: Week 96
Change From Baseline in CD4 Cell Count at Week 48
Time frame: Baseline, Week 48
Change From Baseline in CD4 Cell Count at Week 96
Time frame: Baseline, Week 96
Change From Baseline in Percentage of CD4 Cells at Week 48
Time frame: Baseline, Week 48
Change From Baseline in Percentage of CD4 Cells at Week 96
Time frame: Baseline, Week 96
Percentage of Participants With Plasma HBV DNA < 29 IU/mL at Week 96
This outcome measure was analyzed using a Missing = Failure approach. In this approach, all missing data were treated as HBV DNA ≥ 29 IU/mL. Percentages were rounded-off.
Time frame: Week 96
Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48 by American Association for the Study of Liver Diseases (AASLD) Criteria
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given post baseline visit. The upper limit of the normal range (ULN) for ALT using the 2018 AASLD normal range was ≤ 25 U/L for females and ≤ 35 U/L for males. The Missing = Failure approach was used for this analysis. Percentages were rounded off.
Time frame: Week 48
Percentage of Participants With ALT Normalization at Week 96
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given post baseline visit. The upper limit of the normal range (ULN) for ALT using the 2018 AASLD normal range was ≤ 25 U/L for females and ≤ 35 U/L for males. The Missing = Failure approach was used for this analysis. Percentages were rounded-off.
Time frame: Week 96
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48
HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a post baseline visit. HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative or missing at baseline to positive at a post baseline visit. The Missing = Failure approach was used for this analysis. Percentages were rounded-off.
Time frame: Week 48
Percentage of Participants With HBsAg Loss at Week 96
HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a post baseline visit. HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative or missing at baseline to positive at a post baseline visit. The Missing = Failure approach was used for this analysis. Percentages were rounded-off.
Time frame: Week 96
Participants were enrolled at study sites in the North American, Asian, and European regions.
| Milestone | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF | Open-Label Extension Phase: B/F/TAF From B/F/TAF | Open-Label Extension Phase: B/F/TAF From DTG+F/TDF |
|---|---|---|---|---|
| Started | 122 | 122 | 0 | 0 |
| Completed | 111 | 113 | 0 | 0 |
| Not completed | 11 | 9 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 3 | 0 | 0 |
| Withdrew: Withdrew consent | 2 | 3 | 0 | 0 |
| Withdrew: Investigator's discretion | 2 | 1 | 0 | 0 |
| Withdrew: Death | 2 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 2 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Withdrew: Randomized but never treated | 1 | 0 | 0 | 0 |
| Milestone | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF | Open-Label Extension Phase: B/F/TAF From B/F/TAF | Open-Label Extension Phase: B/F/TAF From DTG+F/TDF |
|---|---|---|---|---|
| Started | 0 | 0 | 95 | 89 |
| Completed | 0 | 0 | 91 | 88 |
| Not completed | 0 | 0 | 4 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 3 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Percentages were rounded-off.
| percentage of participants | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm (Co-primary Endpoint) | 95.0 | 91.0 |
This outcome measure was analyzed using a Missing = Failure approach. In this approach, all missing data were treated as HBV DNA ≥ 29 IU/mL. Percentages were rounded-off.
| percentage of participants | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF |
|---|---|---|
| Percentage of Participants With Plasma Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48 as Defined by Missing = Failure Approach (Co-primary Endpoint) | 63.0 | 43.4 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which was defined as a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Percentages were rounded-off.
| percentage of participants | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm | 87.4 | 87.7 |
| cells/µL | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF |
|---|---|---|
| Change From Baseline in CD4 Cell Count at Week 48 | 200 ± 139.3 | 175 ± 124.7 |
| cells/uL | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF |
|---|---|---|
| Change From Baseline in CD4 Cell Count at Week 96 | 261 ± 161.6 | 229 ± 174.0 |
| percentage of CD4 cells | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF |
|---|---|---|
| Change From Baseline in Percentage of CD4 Cells at Week 48 | 8.43 ± 4.1 | 7.75 ± 4.3 |
| percentage of CD4 cells | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF |
|---|---|---|
| Change From Baseline in Percentage of CD4 Cells at Week 96 | 10.69 ± 5.047 | 10.42 ± 5.096 |
This outcome measure was analyzed using a Missing = Failure approach. In this approach, all missing data were treated as HBV DNA ≥ 29 IU/mL. Percentages were rounded-off.
| percentage of participants | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF |
|---|---|---|
| Percentage of Participants With Plasma HBV DNA < 29 IU/mL at Week 96 | 74.8 | 70.5 |
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given post baseline visit. The upper limit of the normal range (ULN) for ALT using the 2018 AASLD normal range was ≤ 25 U/L for females and ≤ 35 U/L for males. The Missing = Failure approach was used for this analysis. Percentages were rounded off.
| percentage of participants | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF |
|---|---|---|
| Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48 by American Association for the Study of Liver Diseases (AASLD) Criteria | 73.3 | 55.3 |
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given post baseline visit. The upper limit of the normal range (ULN) for ALT using the 2018 AASLD normal range was ≤ 25 U/L for females and ≤ 35 U/L for males. The Missing = Failure approach was used for this analysis. Percentages were rounded-off.
| percentage of participants | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF |
|---|---|---|
| Percentage of Participants With ALT Normalization at Week 96 | 71.7 | 57.4 |
HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a post baseline visit. HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative or missing at baseline to positive at a post baseline visit. The Missing = Failure approach was used for this analysis. Percentages were rounded-off.
| percentage of participants | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF |
|---|---|---|
| Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48 | 12.6 | 5.8 |
HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a post baseline visit. HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative or missing at baseline to positive at a post baseline visit. The Missing = Failure approach was used for this analysis. Percentages were rounded-off.
| percentage of participants | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF |
|---|---|---|
| Percentage of Participants With HBsAg Loss at Week 96 | 22.7 | 14.0 |
Collected over Adverse Events: Up to the last dose date plus 30 days (maximum exposure: 5.1 years); All-Cause Mortality: Up to 5.3 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Blinded Phase: B/F/TAF | 2/122 (1.6%) | 17/121 (14%) | 102/121 (84.3%) |
| Blinded Phase: DTG + F/TDF | 1/122 (0.8%) | 16/122 (13.1%) | 98/122 (80.3%) |
| Open-Label Extension Phase: B/F/TAF From B/F/TAF | 1/95 (1.1%) | 4/95 (4.2%) | 42/95 (44.2%) |
| Open-Label Extension Phase: B/F/TAF From DTG+F/TDF | 0/89 (0%) | 2/89 (2.2%) | 40/89 (44.9%) |
| Event | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF | Open-Label Extension Phase: B/F/TAF From B/F/TAF | Open-Label Extension Phase: B/F/TAF From DTG+F/TDF |
|---|---|---|---|---|
| Covid-19Infections and infestations | 3/121 | 6/122 | 0/95 | 0/89 |
| HaemorrhoidsGastrointestinal disorders | 0/121 | 0/122 | 2/95 | 0/89 |
| Bacterial sepsisInfections and infestations | 0/121 | 0/122 | 0/95 | 1/89 |
| Groin abscessInfections and infestations | 0/121 | 0/122 | 0/95 | 1/89 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 0/121 | 0/122 | 0/95 | 1/89 |
| Alcoholic seizureNervous system disorders | 0/121 | 0/122 | 0/95 | 1/89 |
| Haemorrhoids thrombosedGastrointestinal disorders | 0/121 | 0/122 | 1/95 | 0/89 |
| Anal abscessInfections and infestations | 1/121 | 0/122 | 1/95 | 0/89 |
| Dermal cystSkin and subcutaneous tissue disorders | 0/121 | 0/122 | 1/95 | 0/89 |
| Myocardial ischaemiaCardiac disorders | 1/121 | 0/122 | 0/95 | 0/89 |
| Event | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF | Open-Label Extension Phase: B/F/TAF From B/F/TAF | Open-Label Extension Phase: B/F/TAF From DTG+F/TDF |
|---|---|---|---|---|
| Covid-19Infections and infestations | 48/121 | 52/122 | 5/95 | 4/89 |
| Upper respiratory tract infectionInfections and infestations | 22/121 | 20/122 | 7/95 | 7/89 |
| NasopharyngitisInfections and infestations | 18/121 | 10/122 | 7/95 | 5/89 |
| PyrexiaGeneral disorders | 17/121 | 16/122 | 1/95 | 3/89 |
| Alanine aminotransferase increasedInvestigations | 12/121 | 15/122 | 1/95 | 3/89 |
| DiarrhoeaGastrointestinal disorders | 13/121 | 11/122 | 2/95 | 6/89 |
| Weight increasedInvestigations | 13/121 | 12/122 | 6/95 | 6/89 |
| HeadacheNervous system disorders | 13/121 | 9/122 | 1/95 | 0/89 |
| SyphilisInfections and infestations | 8/121 | 11/122 | 2/95 | 1/89 |
| RashSkin and subcutaneous tissue disorders | 10/121 | 9/122 | 2/95 | 0/89 |
The Safely Analysis Set included participants who were randomized into the study and received at least 1 dose of study drug.
| Age, Categorical(Participants) | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 120 | 121 | 241 |
| >=65 years | 1 | 1 | 2 |
| Age, Continuous(years) | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF | Total |
|---|---|---|---|
| Mean | 33 ± 9.2 | 33 ± 9.4 | 33 ± 9.3 |
| Sex: Female, Male(Participants) | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF | Total |
|---|---|---|---|
| Female | 9 | 2 | 11 |
| Male | 112 | 120 | 232 |
| Ethnicity (NIH/OMB)(Participants) | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 10 | 17 |
| Not Hispanic or Latino | 114 | 112 | 226 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF | Total |
|---|---|---|---|
| Race — Asian | 108 | 106 | 214 |
| Race — White | 10 | 9 | 19 |
| Race — Black | 2 | 6 | 8 |
| Race — Other | 1 | 1 | 2 |
| Region of Enrollment(Participants) | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF | Total |
|---|---|---|---|
| Thailand | 55 | 39 | 94 |
| China | 27 | 29 | 56 |
| Malaysia | 15 | 22 | 37 |
| Taiwan | 5 | 7 | 12 |
| Dominican Republic | 4 | 6 | 10 |
| Turkey | 4 | 5 | 9 |
| Japan | 2 | 5 | 7 |
| Spain | 4 | 3 | 7 |
| Hong Kong | 2 | 3 | 5 |
| United States | 1 | 2 | 3 |
| South Korea | 2 | 0 | 2 |
| Puerto Rico | 0 | 1 | 1 |
| CD4 Cell Count(cells/µL) | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF | Total |
|---|---|---|---|
| Mean | 282 ± 193.1 | 266 ± 194.3 | 274 ± 193.5 |
| CD4 Percentage(percentage of CD4 cells) | Blinded Phase: B/F/TAF | Blinded Phase: DTG + F/TDF | Total |
|---|---|---|---|
| Mean | 16.0 ± 8.62 | 14.8 ± 8.25 | 15.4 ± 8.44 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gileadclinicaltrials.com
Ran from May 2018 to primary completion in Feb 2022, 44 months.
Results were first posted in Mar 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide